Posted on

The risk of heart failure increases with aspirin consumption

 

In people with an underlying risk factor for heart failure, aspirin should never be prescribed as it increases the risk of heart failure by as much as 26%. This finding was published in the ESC Heart Failure journal, which is affiliated with the European Society of Cardiology (ESC). The underlying risk factors include smoking, diabetes, high blood pressure, high cholesterol, obesity, and cardiovascular disease.

This is a path-breaking study as it is the first to report how dangerous aspirin medication is to people having at least one risk factor of heart failure. Although the potentially dangerous link between aspirin consumption and heart failure has been unraveled, the finding needs to be backed up with substantial evidence that confirms the finding. The association of aspirin with heart failure can seem to be baffling to some medical researchers.

In the journal article, researchers explained how the incidence of heart failure was related to people with and without any heart ailment. Thereafter, they also assessed whether the use of a drug could lead to a new diagnosis of heart failure in people who have underlying risk factors. In this study, researchers investigated 30,827 patients with a risk factor for heart failure. These patients were from Western European countries and the US, that is, patients from the developed world.

The age of participants was at least 40 years and above, with the average age being 67 years. At the time of enrolment, they did not have any incidence of heart failure. Based on the usage of aspirin medication, the participants were divided into two groups: users and non-users. The patients who had the first incidence of heart failure were followed up, regardless of whether the attack was fatal or non-fatal as the incidence needed hospitalization.

About 34% of the participants were women. Nearly 25% of the participants were consuming aspirin, that is, 7698 patients in total. In the follow-up period of 5.3 years, heart failure occurred in about 1330 participants. The researchers investigated whether the use of aspirin was truly related to the incidence of heart failure in patients.

They also took into consideration several risk factors: gender, age, body mass index, smoking habit, alcohol consumption, blood pressure, blood cholesterol, creatinine levels, diabetes, cardiovascular disease, etc. Some of the other risk factors for heart failure included treatment of drugs inhibiting the levels of renin, angiotensin, and aldosterone, blockers of calcium channel, beta-blockers, diuretics, and drugs used to lower lipids. The researchers reported that the consumption of aspirin increased the risk of heart failure by about 26%.

 

 

Posted on

The onset of type 1 diabetes may be prevented with existing drug

According to researchers at the University of Colorado, a drug used to treat high blood pressure may also be used as a preventive medication for type 1 diabetes. This study was published in the Journal of Clinical Investigation.  This seems to be an important breakthrough to combat type 1 diabetes. In the clinical investigating laboratory, this discovery was path-breaking on mice and humans with the aid of supercomputers.

In pregnant woman and children, the drug methyldopa was used to treat high blood pressure for the past 50 years. This drug was included in the list of essential drugs at the World Health Organization (WHO).

Many drugs may be used to treat a single condition; however, the path-breaking discovery was completely unrelated to current use of medication. The risk of developing type 1 diabetes increases manifold with the molecule D8, with about 60 percent people with type 1 diabetes being diagnosed with this molecule. Scientists believe that the onset of heart disease could be prevented if the molecule D8 can be blocked specifically.

Every allopathic medication has side-effects. Excessive consumption of acetaminophen can cause damage to liver. Every small molecule approved by FDA was taken into consideration and analyzed with a supercomputer to identify whether the linkage between HLA and DQ8 existed. Each drug exhibited more than thousand orientations. We identified the ones that were associated with DQ8 molecule.

Thousands of drugs were analyzed with a supercomputer. The drug methyldopa was found to block DQ8. Nevertheless, the immune function of remaining cells was not compromised in this case like the way other immunosuppressant drugs. These research studies were conducted over a period of 10 years, but the efficacy was proved in mice and in 20 patients who were diagnosed with type 1 diabetes.

These patients participated in the clinical trial that was conducted at the School of Medicine, University of Colorado. With this discovery, prediction of type 1 diabetes is possible. The ultimate aim of this study was either to delay or to prevent the onset of type 1 diabetes among the people who were at risk of developing diabetes.

The drug used to prevent type 1 diabetes can be administered orally, at least three times a day. The strategy of blocking the expression of a specific molecule can also be used to combat other diseases.This study showed significant improvement in people suffering from diabetes and other autoimmune diseases.

The same approach can also be used to treat other autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis, systemic lupus, etc. To verify the implications of this disease, a larger clinical trial would be conducted at the National Institutes of Health in spring season. A very significant development would be the prevention of type 1 diabetes in people at risk of developing the illness.